Therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and influencing factors
By: Wu, Gang
.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2021Edition: Vol.83(1), Jan-Feb.Description: 120-126p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical sciencesSummary: To explore the therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy
on advanced non-squamous non-small cell lung cancer and its in fluencing factors is the main objective. A
total of 87 patients with advanced non-squamous non-small cell lung cancer treated in our hospital from
October 2016 to May 2018 were enrolled and allocated into control group and observation group according
to their disease conditions and willingness. Paclitaxel and cisplatin chemotherapy regimen was employed
for control group, based on which pembrolizumab was used for observation group. Cellular immunity
indices, cytokine indices, short-term efficacy, adverse reactions, and long-term prognosis were compared,
and the factors affecting short-term ef ficacy and long-term prognosis were analyzed. After treatment,
observation group exhibited increased cluster of differentiation 3+ T lymphocytes, cluster of differentiation
4+ T lymphocytes, and cluster of differentiation 4 +/cluster of differentiation 8+ ratio and decreased cluster
of differentiation 8 + T lymphocytes compared with control group (p<0.05). After treatment, the levels
of interleukin-6 and tumor necrosis factor-alpha in observation group were lower than those in control
group (p<0.05). The short-term ef ficacy and long-term prognosis in observation group were better than
those in control group (p<0.05), but statistically no signi ficant difference in the incidence rate of adverse
reactions was found between the two groups (p>0.05). Decreased cluster of differentiation 4 +/cluster of
differentiation 8+ ratio increased tumor necrosis factor-alpha level and chemotherapy were risk factors for
the poor short-term efficacy and long-term prognosis in patients with advanced non-squamous non-small
cell lung cancer (p<0.05), and clinical stage IV was a risk factor for the unfavorable long-term prognosis as
well (p<0.05). Pembrolizumab combined with paclitaxel and cisplatin chemotherapy regimen can relieve
the cellular immune suppression and alleviate inflammatory responses to improve the short-term efficacy
and long-term prognosis, without raising the incidence rate of severe adverse reactions in the treatment of
advanced non-squamous non-small cell lung cancer
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2021-2022634 |
To explore the therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy
on advanced non-squamous non-small cell lung cancer and its in fluencing factors is the main objective. A
total of 87 patients with advanced non-squamous non-small cell lung cancer treated in our hospital from
October 2016 to May 2018 were enrolled and allocated into control group and observation group according
to their disease conditions and willingness. Paclitaxel and cisplatin chemotherapy regimen was employed
for control group, based on which pembrolizumab was used for observation group. Cellular immunity
indices, cytokine indices, short-term efficacy, adverse reactions, and long-term prognosis were compared,
and the factors affecting short-term ef ficacy and long-term prognosis were analyzed. After treatment,
observation group exhibited increased cluster of differentiation 3+ T lymphocytes, cluster of differentiation
4+ T lymphocytes, and cluster of differentiation 4 +/cluster of differentiation 8+ ratio and decreased cluster
of differentiation 8 + T lymphocytes compared with control group (p<0.05). After treatment, the levels
of interleukin-6 and tumor necrosis factor-alpha in observation group were lower than those in control
group (p<0.05). The short-term ef ficacy and long-term prognosis in observation group were better than
those in control group (p<0.05), but statistically no signi ficant difference in the incidence rate of adverse
reactions was found between the two groups (p>0.05). Decreased cluster of differentiation 4 +/cluster of
differentiation 8+ ratio increased tumor necrosis factor-alpha level and chemotherapy were risk factors for
the poor short-term efficacy and long-term prognosis in patients with advanced non-squamous non-small
cell lung cancer (p<0.05), and clinical stage IV was a risk factor for the unfavorable long-term prognosis as
well (p<0.05). Pembrolizumab combined with paclitaxel and cisplatin chemotherapy regimen can relieve
the cellular immune suppression and alleviate inflammatory responses to improve the short-term efficacy
and long-term prognosis, without raising the incidence rate of severe adverse reactions in the treatment of
advanced non-squamous non-small cell lung cancer
Click on an image to view it in the image viewer
There are no comments for this item.